Long-term outcome of phenobarbital treatment for epilepsy in rural China: A prospective cohort study

Grants

Funding Acknowledgements

We thank all the local primary care physicians, patients, and their families for participating in this study. We thank Dr. Gail Bell for critical review of an earlier version of this article. The study was funded by the Chinese Ministry of Health and Stichting Epilepsie Instellingen Nederland. The sponsors were not directly involved in the study design, collection, analysis, interpretation of data, writing of the report, or decision to submit the report for publication.PK serves on the scientific advisory board of GSK, Pfizer, and UCB Pharma; speaker's bureau of GSK, Sanofi, and UCB Pharma; provides consultancy to Eisai and GSK; and receives research grants from Eisai, Johnson & Johnson, Pfizer, and UCB Pharma. ZH serves on the editorial advisory boards of Chinese Journal of Neurology; has received research support from the Chinese Ministry of Health and the China Association Against Epilepsy; and has been a commissioner of the neurology branch of the Chinese Medical Association. JWS served on scientific advisory boards for GSK, UCB, and Viropharma; has received funding for travel from UCB and Janssen; serves on the editorial boards of Lancet Neurology and Epileptic Disorders; serves on the speaker's bureaus of UCB and GSK; and has received research support from UCB, GSK, the NIH, the European Union Seventh Framework Programme, the Wellcome Trust, WHO, the National Epilepsy Funds of the Netherlands, and the Epilepsy Society. The other authors have no competing interests. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.